Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery11None of the authors had any proprietary interests in Celtrix Pharmaceuticals, Inc. during or after the study.
This study aimed to compare the visual and anatomic results of macular hole surgery in eyes treated with recombinant transforming growth factor-beta-2 (TGF-beta2) or placebo.
The design was a prospective, multicenter, randomized, double-masked, placebo-controlled clinical study.
One hundred thirty eyes with idiopathic macular holes of 1 year or less and a refracted Early Treatment Diabetic Retinopathy Study visual acuity of 20/80 or worse were treated with 1.1 microg recombinant TGF-beta2 or placebo to the macular hole after fluid-gas exchange.
The effect of recombinant TGF-beta2 as an adjunctive agent for macular hole surgery was evaluated.
Closure of the macular hole and change in visual acuity at 3 months were measured.
The 3-month visits were completed for 120 eyes. The macular hole was closed at 3 months in 35 (61.4%) of 57 eyes treated with placebo and 49 (77.8%) of 63 eyes treated with recombinant TGF-beta2 (P = 0.08). The mean visual acuity gain was +6.4 letters in eyes receiving placebo and +8.9 letters in eyes treated with recombinant TGF-beta2 (P = 0.27). Visual acuity improved 2 or more lines in 23 (40.4%) of 57 eyes treated with placebo and 30 (47.6%) of 63 eyes treated with recombinant TGF-beta2 (P = 0.42). Intraocular pressure elevation greater than 30 mmHg was more common 2 weeks after surgery in eyes treated with recombinant TGF-beta2 (P < 0.001).
Recombinant TGF-beta2 resulted in a similar proportion of successful closure of macular holes as placebo. There was no statistically significant visual acuity benefit with the use of recombinant TGF-beta2 for the treatment of macular holes.
Pharmacology, Toxicology and Pharmaceutical Science
1
3%
Nursing and Health Professions
1
3%
Agricultural and Biological Sciences
1
3%
Engineering
1
3%
Other
0
0%
Unknown
9
29%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 April 2012.
All research outputs
#12,044,431
of 33,872,748 outputs
Outputs from Ophthalmology
#4,137
of 8,746 outputs
Outputs of similar age
#19,381
of 46,684 outputs
Outputs of similar age from Ophthalmology
#18
of 30 outputs
Altmetric has tracked 33,872,748 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,746 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.7. This one is in the 29th percentile – i.e., 29% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 46,684 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 3rd percentile – i.e., 3% of its contemporaries scored the same or lower than it.
